Savara Reports Positive Interim Results of Aironite Phase 2 Study

Savara Reports Positive Interim Results of Aironite Phase 2 Study

Pharmaceutical company Savara reported positive interim results from an ongoing phase 2 study of Aironite in patients with pulmonary hypertension (PH) from multiple different etiologies. The company said Aironite significantly improved multiple hemodynamic measures, with most pronounced improvements in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). It also resulted in significant overall decreases in right atrial pressure, systolic and diastolic right ventricular pressure, systolic […]

Read More ˃